These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 20439487

  • 1. Efficacy of a methylphenidate transdermal system versus t.i.d. methylphenidate in a laboratory setting.
    Pelham WE, Waxmonsky JG, Schentag J, Ballow CH, Panahon CJ, Gnagy EM, Hoffman MT, Burrows-MacLean L, Meichenbaum DL, Forehand GL, Fabiano GA, Tresco KE, Lopez-Williams A, Coles EK, González MA.
    J Atten Disord; 2011 Jan; 15(1):28-35. PubMed ID: 20439487
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK.
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [Abstract] [Full Text] [Related]

  • 5. Methylphenidate and comorbid anxiety disorder in children with both chronic multiple tic disorder and ADHD.
    Gadow KD, Nolan EE.
    J Atten Disord; 2011 Apr; 15(3):246-56. PubMed ID: 20378921
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [Abstract] [Full Text] [Related]

  • 9. A dose-ranging study of a methylphenidate transdermal system in children with ADHD.
    Pelham WE, Manos MJ, Ezzell CE, Tresco KE, Gnagy EM, Hoffman MT, Onyango AN, Fabiano GA, Lopez-Williams A, Wymbs BT, Caserta D, Chronis AM, Burrows-Maclean L, Morse G.
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):522-9. PubMed ID: 15908834
    [Abstract] [Full Text] [Related]

  • 10. Transdermal methylphenidate system: old wine in a new bottle.
    Bukstein OG.
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):661-5. PubMed ID: 19442029
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network.
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [Abstract] [Full Text] [Related]

  • 13. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R.
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [Abstract] [Full Text] [Related]

  • 14. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
    Brams M, Mao AR, Doyle RL.
    Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Methylphenidate transdermal system.
    Mays DA, Findling R.
    J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1223. PubMed ID: 16292112
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
    Sonuga-Barke EJ, Swanson JM, Coghill D, DeCory HH, Hatch SJ.
    BMC Psychiatry; 2004 Sep 30; 4():28. PubMed ID: 15458569
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun 30; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 20. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B.
    Pediatrics; 2006 Sep 30; 118(3):e704-10. PubMed ID: 16950962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.